azacitidine has been researched along with Emesis in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (54.55) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Q; Li, M; Qiu, H; Sun, A; Wu, D; Wu, X; Zhang, J; Zhou, L | 1 |
| Adès, L; Ame, S; Beyne-Rauzy, O; Braun, T; Charbonnier, A; Delaunay, J; Dreyfus, F; Fenaux, P; Prebet, T; Raffoux, E; Stammatoullas, A; Vey, N; Wattel, E | 1 |
| Abdel-Wahab, O; Berube, C; Coutre, S; Gallegos, L; Gotlib, JR; Greenberg, P; Levine, R; Liedtke, M; Medeiros, BC; Mitchell, BS; Pollyea, DA; Zehnder, J; Zhang, B | 1 |
| Aribi, A; Cortes, J; Davisson, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, HM; O'Brien, S; Ravandi, F; Shan, J | 1 |
| Creagan, ET; Hartmann, LC; Loprinzi, CL; Schaid, DJ | 1 |
| Cohen, FB; Custodio, MC; Decter, JA; Lippman, AJ | 1 |
| Muggia, FM; Slavik, M; Von Hoff, DD | 1 |
| Keller, JW; Miller, DS; Vogler, WR | 1 |
| Bellet, RE; Berd, D; Catalano, RB; Mastrangelo, MJ | 1 |
| Baehner, RL; Berkow, RL; Weetman, RM; Weisman, SJ | 1 |
| Hahn, RG; Moertel, CG; Reitemeier, RJ; Schutt, AJ | 1 |
2 review(s) available for azacitidine and Emesis
| Article | Year |
|---|---|
New antineoplastic drugs and their proper use.
Topics: Antineoplastic Agents; Asparaginase; Azacitidine; Bleomycin; Bone Marrow Diseases; Dacarbazine; Doxorubicin; Humans; Liver; Nausea; Neoplasms; Nitrosourea Compounds; Pancreatitis; Pulmonary Fibrosis; Vomiting | 1976 |
5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia.
Topics: Animals; Azacitidine; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemistry; Europe; Female; Humans; Kinetics; Leukemia L1210; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukopenia; Liver; Nausea; Neoplasms, Experimental; Neuromuscular Diseases; RNA, Messenger; United States; Vomiting | 1976 |
5 trial(s) available for azacitidine and Emesis
| Article | Year |
|---|---|
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hydroxamic Acids; In Vitro Techniques; Middle Aged; Myelodysplastic Syndromes; Nausea; Neutropenia; Recurrence; Risk Factors; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting; Vorinostat | 2014 |
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; fms-Like Tyrosine Kinase 3; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid; Male; Middle Aged; Mutation; Nausea; Nuclear Proteins; Nucleophosmin; Prognosis; Remission Induction; Thalidomide; Treatment Outcome; Vomiting | 2013 |
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 7; Decitabine; Drug Administration Schedule; Fatigue; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; Vomiting | 2007 |
A phase II study of 5,6-dihydro-5-azacytidine hydrochloride in disseminated malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biopsy; Chest Pain; Female; Humans; Immunologic Factors; Infusions, Intravenous; Male; Melanoma; Middle Aged; Nausea; Remission Induction; Risk Factors; Severity of Illness Index; Survival Rate; Vomiting | 1993 |
Phase II study of 5-azacytidine (NSC-102816) in the treatment of advanced gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Azacitidine; Blood Cell Count; Blood Platelets; Clinical Trials as Topic; Cytidine; Female; Gastrointestinal Neoplasms; Humans; Leukocyte Count; Male; Middle Aged; Nausea; Triazines; Vomiting | 1972 |
4 other study(ies) available for azacitidine and Emesis
| Article | Year |
|---|---|
Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nausea; Oncogene Proteins, Fusion; Sulfonamides; Transplantation, Haploidentical; Treatment Outcome; Vomiting | 2020 |
5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia.
Topics: Agranulocytosis; Azacitidine; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Nausea; Neoplasm Metastasis; Vomiting | 1976 |
Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma.
Topics: Azacitidine; Bone Marrow; Dacarbazine; Drug Evaluation; Drug Resistance; Female; Humans; Injections, Subcutaneous; Male; Melanoma; Neoplasm Metastasis; Vomiting | 1978 |
5-Azacytidine: acute central nervous system toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Central Nervous System; Child; Humans; Leukemia, Monocytic, Acute; Male; Nausea; Vomiting | 1985 |